INDIA – Mylab Discovery Solutions, a diagnostic solutions provider, announced a strategic alliance with Shilpa Biologicals Pvt Ltd (a 100 percent subsidiary of Shilpa Medicare Ltd), a specialist manufacturer of vaccines and a wide range of biologicals.
Beginning with the Covid-19 vaccine manufacturing opportunity, the parties intend to strengthen their relationship by expanding their product portfolio in a variety of other areas, including biosimilars, other vaccines, and diagnostics.
The first vaccine project under this long-term partnership is currently under the final evaluation phase and the manufacturing is expected to start by March 2022.
Mylab intends to leverage Shilpa Biologicals’ technical expertise in the development and manufacture of biopharmaceuticals through its world-class facility in Dharwad, and eventually develop world-class diagnostics, vaccines, and therapeutics to expand its presence in the healthcare market.
”Our strategy to offer value-driven innovation helped us disrupt the diagnostics market in India. We have proudly served millions of people across the globe with our diagnostics and we believe we can drive similar milestones in the vaccine and therapeutics space,” Mylab Corporate Strategy Director Sujit Jain noted.
Shilpa Biologicals will meet these requirements by utilizing its 11-acre integrated research and development/manufacturing facility in Dharwad.
Shilpa Biologicals Managing Director Vinay Konaje stated that the company has deep expertise in R&D-driven manufacturing of complex vaccines and biologicals at a global scale.
”Our partnership with Mylab will help us unlock significant value in the newer market segments of preventive healthcare. Together, we aim to create products that can serve global markets and establish market leadership,” he added.
This collaboration will focus on the development of novel technologies that will allow for the production of safe, effective, and cost-effective vaccines and therapeutics.
Meanwhile, Siemens Healthineers, a German health group, agreed to buy Varian Medical Systems for US$16.4 billion in November last year, with the goal of creating the global leader in cancer care solutions.
The acquisition of the radiation oncology systems and software maker builds on Siemens Healthineers and Varian’s long-standing collaboration to develop improved cancer therapy solutions.
While tech mergers and hospital megamergers make headlines, Medline, a medical supply maker and distributor, was named the biggest M&A deal of 2021.
A group of private equity firms led by Blackstone Group, Carlyle Group, and Hellman & Friedman acquired a majority stake in Medline in a deal worth more than US$30 billion, including debt.
Also, Private equity firms Bain Capital and Hellman & Friedman have paid US$17 billion for Athenahealth, an electronic health records vendor for physician practices.
The investment, which provides electronic health records and physician practice tools, is expected to be completed in the first quarter of 2022.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
